Adelani Wakili Tijani

Adelani Wakili Tijani

Auto-generated profile, based on publicly available information

Adelani Wakili Tijani

Nursing Science Department, Federal University Oye Ekiti, Oye Ekiti, Nigeria

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Bio-X Research
Verified
Journal Article
Closed access
MOMathew Folaranmi OLANIYAN
Mathew Folaranmi OLANIYAN
AOAyowole Abraham Oladele
Ayowole Abraham Oladele
ATAdelani Tijani
Adelani Tijani
MMMusa Abidemi Muhibi
Musa Abidemi Muhibi
TOTolulope Busayo Olaniyan
Tolulope Busayo Olaniyan
Background:Disease epidemiology encompasses a wide range of health conditions, divided into communicable and noncommunicable diseases.Aim and Objective:This systematic review investigates the intricate connection between genetic susceptibility and disease development within these categories. Understanding genetic factors is crucial for improving prevention, diagnosis, and treatment strategies. The central research question is as follows: Which genes are linked to susceptibility to communicable and noncommunicable diseases, and how do these genetic elements affect susceptibility? We hypothesize that an exhaustive analysis of the literature will reveal numerous genes associated with both types of diseases, revealing the complex genetic landscape influencing susceptibility.Methodology:This systematic review follows a rigorous methodology, including comprehensive search strategies, well-defined inclusion and exclusion criteria, publication bias assessment, data extraction, quality evaluation, and data synthesis, adhering to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to ensure transparency and ethical presentation. Several databases, including PubMed, Embase, Springer Nature, AJOL, CrossRef, Scopus, and Web of Science, were systematically searched to retrieve published articles.Findings:In communicable diseases, the genetic factors influencing susceptibility extend beyond well-established genes, warranting further investigation under conditions such as COVID-19, HIV, tuberculosis, and hepatitis B. Noncommunicable diseases, such as cardiovascular diseases, cancer, neurological disorders, and metabolic disorders, offer promising avenues for exploring additional genetic variations. Research gaps include understanding the functional impact of the identified polymorphisms, their interaction with environmental factors, and their implications for rare diseases.Conclusion:Genome-wide association studies and gene editing therapies have the potential to expand our understanding and therapeutic options for genetically based diseases. This comprehensive review contributes to the evolving landscape of genetic susceptibility and its implications for public health and personalized medicine.

14 November 2024 in Discover Immunity
Verified
Journal Article
Open access
PDF file
MOMathew Folaranmi OLANIYAN
Mathew Folaranmi OLANIYAN
OOOlufemi David Olaniyi
Olufemi David Olaniyi
TOTolulope Busayo Olaniyan
Tolulope Busayo Olaniyan
OAObataze Josephine Akpoyovwere
Obataze Josephine Akpoyovwere
ATAdelani Wakili Tijani
Adelani Wakili Tijani
MOMathew Folaranmi Olaniyan
Mathew Folaranmi Olaniyan
Background Immunosuppressive agents are crucial for managing autoimmune diseases and organ transplants, but synthetic options often cause significant side effects. Nigerian medicinal plants, rich in bioactive compounds, present a promising natural alternative for immune modulation. This systematic review examines the immunosuppressive properties of phytochemicals and phytonutrients from Nigerian plants, focusing on their mechanisms of action and therapeutic potential. Materials and methods A comprehensive literature search was conducted following PRISMA guidelines across major databases, including PubMed, Scopus, Google Scholar, the Cochrane Library, Web of Science, and AJOL. The search covered studies published between January 2000 and August 2024 using keywords like "immunosuppressive," "phytochemicals," "phytonutrients," and specific Nigerian plants. Studies were included if they investigated the immunosuppressive effects of Nigerian plants through in vitro, in vivo, or clinical methods. Non-immunological studies were excluded. Data extraction and quality assessment were independently performed by two reviewers. Results A total of 141 studies were reviewed, identifying several Nigerian plants with notable immunosuppressive effects. Azadirachta indica (neem) demonstrated a strong ability to inhibit T-cell proliferation and cytokine production. Vernonia amygdalina (bitter leaf) and Garcinia kola (bitter kola) were effective in reducing pro-inflammatory cytokines and modulating lymphocyte activity. Other plants, including Ocimum gratissimum (scent leaf), Allium sativum (garlic), and Zingiber officinale (ginger), exhibited promising immunosuppressive properties by regulating cytokine release and immune cell activation. These findings suggest that Nigerian medicinal plants offer diverse and effective immunosuppressive agents, working through mechanisms like cytokine inhibition and signaling pathway modulation. Conclusion This review highlights the therapeutic potential of Nigerian phytochemicals as immunosuppressive agents, encouraging further research to explore their clinical applications and integration into current treatment frameworks. Future clinical trials are essential to validate their efficacy and safety, with potential uses in autoimmune disease management, inflammatory conditions, and organ transplantation.

21 November 2024 in Discover Immunity
Verified
Journal Article
Open access
PDF file
MOMathew Folaranmi OLANIYAN
Mathew Folaranmi OLANIYAN
KAKemi Felicia Ajiboye
Kemi Felicia Ajiboye
OOOgbeche Richard Ochagu
Ogbeche Richard Ochagu
TOTolulope Busayo Olaniyan
Tolulope Busayo Olaniyan
TATaiwo Medinat Adeniran
Taiwo Medinat Adeniran
MOMathew Folaranmi Olaniyan
Mathew Folaranmi Olaniyan
Background Co-infection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) poses significant clinical challenges, particularly in high-prevalence regions. The presence of anti-HBe antibodies can offer insights into immune responses and disease progression in co-infected patients. Objectives This study aims to investigate the prevalence and clinical significance of anti-HBe antibodies in HBV and HIV co-infected patients in Warri, Nigeria, while analyzing their relationship with HIV-specific antibody profiles. Methods A cross-sectional study involving 200 HBeAg and HIVp24 seropositive patients was conducted. Blood samples were analyzed for anti-HBe using ELISA, alongside assessments for HBeAg and HIVp24. HIV-specific antibodies were detected using Western blot. Data were analyzed using chi-square tests and logistic regression models (IBM SPSS 23.0). Results The study enrolled 200 patients with dual seropositivity for HBeAg and HIVp24. Among these, 150 patients had confirmed HBeAg positivity, of whom 68 (45%) tested positive for anti-HBe. This presence was significantly associated with HIVp24 positivity (p = 0.04). Anti-HBe levels positively correlated with HIV-specific antibodies, with higher mean anti-HBe expression in patients with antibodies to gp120 (1.8 ± 0.4 AU/mL) and gp41 (1.7 ± 0.3 AU/mL). The odds ratio for anti-HBe presence with HIV-specific antibodies was 2.3 (95% CI: 1.5–3.5, p = 0.008). Conclusion The findings indicate a prevalent presence of anti-HBe antibodies among HBeAg-positive HIV co-infected patients, highlighting significant correlations with HIV-specific antibodies. This underscores the complex immune interactions between HBV and HIV, emphasizing the need for integrated management strategies and the potential role of anti-HBe as a marker for disease progression.

1 January 2023 in CURRENT TRENDS IN LIFE SCIENCES RESEARCH
Verified
Journal Article
Closed access
OAOlubukola Adeaga
Olubukola Adeaga
ATAdelani Tijani
Adelani Tijani